"On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, Inc. in the United States District Court for the District of Delaware, asserting that Illumina's spatial technology products infringed on patents covering technology for spatial transcriptomics, which allows researchers to study gene activity within a cell's tissue. U.S. Patent Nos. 11,008,607, 11,549,138, 12,234,505, and 12,297,487 are owned by Prognosys Biosciences and have significant applications in cancer research, neuroscience and immunology."
"In February 2025, Illumina announced its own "'spatial technology program,' for "whole-transcriptome profiling with cellular resolution and high sensitivity." Illumina's subsequent presentations and product descriptions revealed a workflow that infringed on the '607, '138, '505, and '487 patents, 10x Genomics and Prognosys Biosciences argued. Specifically, the filing detailed Illumina's process as including the capture of messenger RNA (mRNA) from tissue, its conversion to complementary DNA (cDNA) tagged with a location barcode, and subsequ"
10x Genomics and Prognosys Biosciences filed a patent infringement complaint against Illumina in the U.S. District Court for the District of Delaware on October 21. The complaint asserts that Illumina's spatial technology products infringe Prognosys-owned patents U.S. Patent Nos. 11,008,607; 11,549,138; 12,234,505; and 12,297,487 covering spatial transcriptomics. The patents have applications in cancer research, neuroscience, and immunology. 10x is the exclusive licensee and reported approximately $2 billion invested in related R&D. Prognosys co-founder Dr. Mark S. Chee is named as an inventor on the patent family. The complaint describes Illumina's announced spatial technology program and a workflow capturing mRNA, converting it to cDNA tagged with location barcodes.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]